- News & Media
Tikcro is pursuing the discovery and pre-clinical development of product candidates leveraging a license agreement with the Weizmann Institute of Science in Israel. This engagement has resulted in promising potential therapeutic antibodies for the treatment of cancer. Leveraging unique immunization technology for the generation of antibodies, this approach shows early success in our pipeline. Going forward, in 2017 through 2018 we plan to promote early-stage antibody candidates into rigorous pre-clinical trials and aim to amass sufficient data for further progress and clinical trials.
We are currently focused on antibody drug-candidates for the stimulation of the self-immune system to combat various types of cancer. We expect our product candidate antibodies to block the ligand/receptor linkage of certain biological pathways, for example CTLA-4 and other immune pathways, and by blocking these pathways to prevent the inhibition of patients’ self-immune system and its ability to attack cancerous cells. This prevention is known to have positive clinical effects and to extend overall survival.